CN103533950A - Vegf拮抗剂在治疗血管生成眼病中的用途 - Google Patents

Vegf拮抗剂在治疗血管生成眼病中的用途 Download PDF

Info

Publication number
CN103533950A
CN103533950A CN201280005207.7A CN201280005207A CN103533950A CN 103533950 A CN103533950 A CN 103533950A CN 201280005207 A CN201280005207 A CN 201280005207A CN 103533950 A CN103533950 A CN 103533950A
Authority
CN
China
Prior art keywords
vegf antagonist
dosage
vegf
patient
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280005207.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·D·扬科普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103533950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN103533950A publication Critical patent/CN103533950A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201280005207.7A 2011-01-13 2012-01-11 Vegf拮抗剂在治疗血管生成眼病中的用途 Pending CN103533950A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161432245P 2011-01-13 2011-01-13
US61/432,245 2011-01-13
US201161434836P 2011-01-21 2011-01-21
US61/434,836 2011-01-21
US201161561957P 2011-11-21 2011-11-21
US61/561,957 2011-11-21
PCT/US2012/020855 WO2012097019A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Publications (1)

Publication Number Publication Date
CN103533950A true CN103533950A (zh) 2014-01-22

Family

ID=45507924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280005207.7A Pending CN103533950A (zh) 2011-01-13 2012-01-11 Vegf拮抗剂在治疗血管生成眼病中的用途

Country Status (13)

Country Link
US (14) US9254338B2 (https=)
EP (4) EP3763379A1 (https=)
JP (6) JP2014503555A (https=)
KR (8) KR20260004598A (https=)
CN (1) CN103533950A (https=)
AU (5) AU2012205599B2 (https=)
BR (1) BR112013017752A8 (https=)
CA (1) CA2824422A1 (https=)
HK (1) HK1244693A1 (https=)
IL (3) IL295359A (https=)
MX (3) MX349901B (https=)
SG (4) SG10201509193UA (https=)
WO (1) WO2012097019A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001457A (zh) * 2014-11-25 2017-08-01 瑞泽恩制药公司 用于治疗血管性眼病的方法和制剂
CN107312093A (zh) * 2016-04-26 2017-11-03 韩国普瑞姆药物股份有限公司 血管内皮生长因子融合蛋白
CN111465407A (zh) * 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN112040978A (zh) * 2017-11-16 2020-12-04 伊维希比奥公司 治疗或预防特发性息肉状脉络膜血管病变（ipcv）的方法
CN114306575A (zh) * 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2025036488A1 (en) * 2023-08-17 2025-02-20 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
KR20260004598A (ko) 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
TWI738632B (zh) * 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
CA2977738A1 (en) * 2015-02-26 2016-09-01 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017046140A1 (en) * 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
US20180353464A1 (en) * 2015-11-24 2018-12-13 Indiana University Research And Technology Corporation Composition for blocking angiogenesis
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
RU2765728C2 (ru) * 2016-05-25 2022-02-02 Сантен Фармасьютикал Ко., Лтд. Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
JP7561433B2 (ja) * 2019-05-28 2024-10-04 学校法人順天堂 糖尿病網膜症の予防又は治療薬
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
AU2020345174A1 (en) * 2019-09-12 2022-03-31 Lupin Limited Modified dosing of VEGF inhibitors for ophthalmic use
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
AU2020397053A1 (en) 2019-12-06 2022-06-23 Regeneron Pharmaceuticals, Inc. VEGF mini-traps and methods of use thereof
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
AU2021287906B2 (en) * 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
WO2022186335A1 (ja) * 2021-03-03 2022-09-09 学校法人自治医科大学 副作用の予測方法およびそのための装置
EP4649959A2 (en) * 2021-04-14 2025-11-19 Kodiak Sciences Inc. Methods of treating an eye disorder
IL308505A (en) * 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024168252A2 (en) * 2023-02-10 2024-08-15 Yale University Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy
WO2024263995A1 (en) * 2023-06-23 2024-12-26 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
WO2003039404A2 (en) 2001-11-09 2003-05-15 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
JP2003309411A (ja) 2002-04-17 2003-10-31 Alps Electric Co Ltd 複合アンテナ
WO2004072320A2 (en) 2003-02-07 2004-08-26 Pavco, Inc. Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths
US7052691B2 (en) 2003-03-28 2006-05-30 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US20040266688A1 (en) 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
AU2004242586C1 (en) 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005087808A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
EP1753442A2 (en) 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
MXPA06014689A (es) 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PL1802334T3 (pl) 2004-10-21 2013-01-31 Genentech Inc Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
EP1917024A2 (en) 2005-08-12 2008-05-07 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a vegf antagonist
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20260004598A (ko) 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN107115294B (zh) 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
JP6071099B1 (ja) 2014-01-25 2017-02-01 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管の新生又は成長を抑制する融合タンパク質及びその用途
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP4122486A1 (en) 2017-11-30 2023-01-25 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat diabetic retinopathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NGUYEN Q D: "《 A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration》", 《OPHTHALMOLO》 *
THOMSON REUTERS INTEGRITY.: "《 VEGF Trap-Eye final phase ii results in age-related macular degeration presented at 2008 Retina Society Meeting》", 《2008 RETINA SOCIETY MEETING》 *
许为青，等: "《VEGF及其受体拮抗剂的临床意义》", 《国外医学耳鼻咽喉科学分册》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001457A (zh) * 2014-11-25 2017-08-01 瑞泽恩制药公司 用于治疗血管性眼病的方法和制剂
US20190117767A1 (en) * 2014-11-25 2019-04-25 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US11071780B2 (en) 2014-11-25 2021-07-27 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
CN114306575A (zh) * 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
CN107312093A (zh) * 2016-04-26 2017-11-03 韩国普瑞姆药物股份有限公司 血管内皮生长因子融合蛋白
CN112040978A (zh) * 2017-11-16 2020-12-04 伊维希比奥公司 治疗或预防特发性息肉状脉络膜血管病变（ipcv）的方法
CN111465407A (zh) * 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation
WO2025036488A1 (en) * 2023-08-17 2025-02-20 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema

Also Published As

Publication number Publication date
US12268730B2 (en) 2025-04-08
HK1244693A1 (en) 2018-08-17
US20210023173A1 (en) 2021-01-28
US20190046609A1 (en) 2019-02-14
AU2012205599B2 (en) 2016-10-20
US11559564B2 (en) 2023-01-24
SG10202111177VA (en) 2021-11-29
US20180339018A1 (en) 2018-11-29
JP2025169389A (ja) 2025-11-12
JP2019167366A (ja) 2019-10-03
AU2017200290A1 (en) 2017-02-02
US11730794B2 (en) 2023-08-22
JP2024001190A (ja) 2024-01-09
CA2824422A1 (en) 2012-07-19
US11253572B2 (en) 2022-02-22
SG10201802789VA (en) 2018-05-30
KR20180023015A (ko) 2018-03-06
WO2012097019A1 (en) 2012-07-19
US20210308216A1 (en) 2021-10-07
US20170202911A1 (en) 2017-07-20
AU2017200290B2 (en) 2019-01-03
EP2663325A1 (en) 2013-11-20
AU2024204677A1 (en) 2024-07-25
US11986511B2 (en) 2024-05-21
IL260167A (en) 2018-07-31
US20240123030A1 (en) 2024-04-18
MX349901B (es) 2017-08-18
JP2014503555A (ja) 2014-02-13
JP2021193115A (ja) 2021-12-23
AU2012205599A1 (en) 2013-07-18
US10130681B2 (en) 2018-11-20
EP3763379A1 (en) 2021-01-13
KR20210030510A (ko) 2021-03-17
BR112013017752A8 (pt) 2018-01-09
SG10201509193UA (en) 2015-12-30
US20160101152A1 (en) 2016-04-14
AU2021200935A1 (en) 2021-03-11
US20190247463A1 (en) 2019-08-15
KR20190049934A (ko) 2019-05-09
KR20240110092A (ko) 2024-07-12
JP7733706B2 (ja) 2025-09-03
EP4360709A3 (en) 2024-07-03
IL295359A (en) 2022-10-01
US11975045B2 (en) 2024-05-07
NZ612593A (en) 2015-03-27
US9669069B2 (en) 2017-06-06
KR20260004598A (ko) 2026-01-08
US20130295094A1 (en) 2013-11-07
US10828345B2 (en) 2020-11-10
US10857205B2 (en) 2020-12-08
EP3222285A1 (en) 2017-09-27
MX385629B (es) 2025-03-18
EP4360709A2 (en) 2024-05-01
JP2017061467A (ja) 2017-03-30
MX2021006092A (es) 2022-05-18
MX2013007847A (es) 2013-07-29
KR20220097542A (ko) 2022-07-07
US9254338B2 (en) 2016-02-09
US20210085753A1 (en) 2021-03-25
AU2019202260A1 (en) 2019-04-18
US10888601B2 (en) 2021-01-12
KR20200077622A (ko) 2020-06-30
IL227160B (en) 2019-02-28
US20250152669A1 (en) 2025-05-15
US20210121524A1 (en) 2021-04-29
US20220273764A1 (en) 2022-09-01
BR112013017752A2 (pt) 2017-08-29
KR20140043313A (ko) 2014-04-09
US11707506B2 (en) 2023-07-25
US20210308217A1 (en) 2021-10-07
SG191334A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
US12268730B2 (en) Use of a VEGF antagonist to treat angiogenic eye disorders
US10973879B2 (en) Use of a VEGF antagonist to treat angiogenic eye disorders
HK40044750A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40109837A (en) Use of a vegf antagonist to treat angiogenic eye disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140122